AstraZeneca has entered a strategic partnership with San Francisco-based Algen Biotechnologies, agreeing to pay up to $555 million to leverage Algen's AI-driven AlgenBrain platform. This platform integrates single-cell CRISPR gene editing with artificial intelligence to identify novel target-disease relationships in immunological disorders. The collaboration aims to accelerate drug discovery by harnessing cutting-edge AI techniques combined with functional genomics. The deal marks a significant investment in AI-powered target identification and drug development strategies within immunology. Algen’s platform offers unprecedented single-cell resolution and mechanistic insights, providing a foundation for discovering therapeutics in complex immune-mediated diseases. AstraZeneca anticipates this will enhance their immunology pipeline and foster development of next-generation precision medicines.